The Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Industry is expected to reach US$ 7.88 billion in 2023 and increase at a CAGR of 9.5% from 2023 to 2033. By 2033, the sector is predicted to be worth an incredible US$ 19.52 billion, owing to the rising prevalence of cancer and other targets.
In the case of neuromuscular illnesses, diagnosis is an important step towards effective therapy. Physicians use a thorough approach, including physical exams and specialized diagnostic testing. A detailed medical history examination is required, including an investigation into family occurrences of neuromuscular disease symptoms, to better comprehend and evaluate the patient’s condition.
Request Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16249
The global nucleic acid and gene therapies in the neuromuscular disorders market are driven by major factors such as a rise in government initiatives to ensure early diagnosis, an increase in awareness about genetic disorders, an upsurge in research and development activities, and improvement in healthcare infrastructure.
Factors including the expanding investments by key market players, a strong product portfolio, as well as a high prevalence of target diseases, and interest in innovative and new therapies are expected to escalate the market growth in the forthcoming years. In addition, the increased investment in research and development by government and private organizations is anticipated to further create lucrative avenues for market growth over the analysis period.
In recent years, the rapid technological advancements in cellular and molecular biology in genomics research are other factors that have been contributing greatly to the market growth. The academicians, researchers, and in-house researchers of major market companies with significant funding have all played critical roles.
The frequency of cardiovascular diseases is increasing in many industrialized countries, and there is a growing need to cure these diseases in less time, resulting in players investing extensively in research and development of highly effective and innovative therapeutics such as gene therapy. The prevalence of rare diseases such as cardiovascular and cancer diseases will have a positive impact on the demand for gene therapy applications. This in turn is likely to expand the market growth shortly.
Currently, only a few market players are dominating the market growth, and are significantly contributing to the market’s expansion. The core members who are working on item dispatching and other important coordinated activities to strengthen their market reach globally. To increase their cancer gene therapy research and product portfolio, local and small market players are increasingly partnering and developing alliances with large market players.
Key Takeaways from the Global Nucleic Acid and Gene Therapies in Neuromuscular Disorders Industry Study:
- Global Nucleic Acid And Gene Therapies in Neuromuscular Disorders Market was valued at US$ 7.19 Bn by 2022-end
- From 2018 to 2022, the market demand expanded at a CAGR of 5%
- By Therapy, the Spinal Muscular Atrophy segment of the market constitutes the bulk of the market with a market share of 46%
- By Application, the Hospitals segment dominates the market with a share of 45%
- From 2023 to 2033, Nucleic Acid And Gene Therapies in Neuromuscular Disorders sales are expected to flourish at a CAGR of 5%.
- By 2033, the market value of Nucleic Acid And Gene Therapies in Neuromuscular Disorders is expected to reach US$ 52 Bn.
Increasing research and development, as well as the growing prevalence of neuromuscular disease are the major factors that are expected to accelerate the growth of the Nucleic Acid And Gene Therapies in Neuromuscular Disorders Market during the forecast period, remarks an FMI analyst.
Ask An Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16249
Competitive Landscape:
Prominent players in the Nucleic Acid And Gene Therapies In the Neuromuscular Disorders market are Pfizer, Inc., F. Hoffmann-La Roche Ltd., UCB Pharma, Biogen, Astellas Pharma, Inc., Novartis AG, Abbott Laboratories, Inc., and Sanofi, among others.
Recent Developments in the Global Nucleic Acid and Gene Therapies in Neuromuscular Disorders Industry:
- In May 2021, Biogen and Capsigen collaborated to discover as well as develop novel AAV Capsids with enhanced properties to facilitate the development of new gene therapies for targeted CNS and Neuromuscular Disorders. Capsigen’s screening technology is designed to produce dose-optimized, fit-for-purpose vectors that may have applicability across Biogen’s gene therapy pipeline. Capsigen received a $15 million upfront payment and is eligible to receive potential research, development, and commercial milestone payments.
- In June 2019, Vertex Pharmaceuticals Incorporated announced the enhancement of its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) by expanding its collaboration with CRISPR Therapeutics and acquiring Exonics Therapeutics. Vertex and CRISPR Therapeutics had expanded their collaboration and entered into an exclusive licensing agreement to discover and develop gene editing therapies for the treatment of DMD and DM1.
Know More About What the Global Nucleic Acid and Gene Therapies in Neuromuscular Disorders IndustryReport Covers
Future Market Insights offers an unbiased analysis of the global Nucleic Acid And Gene Therapies in the Neuromuscular Disorders Market, providing historical data for 2018-2022 and forecast statistics from 2023-2033. To understand opportunities in the Nucleic Acid And Gene Therapies in the Neuromuscular Disorders Market, the market is segmented based on disorder, therapy, and application, across five major regions.
Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-16249
Key Segments Covered in the Global Nucleic Acid and Gene Therapies in Neuromuscular Disorders Industry Analysis
Global Nucleic Acid and Gene Therapies in Neuromuscular Disorders Industry by Disorder:
- Motor Neuron Diseases
- Neuropathies
- Neuromuscular Junction Disorders
- Myopathies including Muscular Dystrophies
Global Nucleic Acid and Gene Therapies in Neuromuscular Disorders Industry by Therapy:
- AAV Gene Therapy
- Postnatal Gene Therapy
- Spinal Muscular Atrophy
Global Nucleic Acid and Gene Therapies in Neuromuscular Disorders Industry by Application
- Hospitals
- Specialty Clinics
- Ambulatory Surgery Centers
Global Nucleic Acid and Gene Therapies in Neuromuscular Disorders Industry by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
